Autobio forming a pattern of immunodiagnostic products and microbiological te
Founded in 1999, Antu Biological is specialized in the development, production and sales of in vitro diagnostic reagents and instruments, forming a pattern of immunodiagnostic products and microbiological testing products. The company's products cover a wide range of testing fields from infectious diseases to non-infectious diseases, and can meet the various testing needs of end users. The reagents cover infectious diseases, tumors, reproductive endocrinology, thyroid function, liver fibrosis, eugenics, diabetes, hypertension, heart disease, genitourinary tract diseases, respiratory diseases, bacterial isolation and culture, identification and susceptibility analysis and other testing fields. In addition, the company has always insisted on the joint development of reagents and instruments, and the related equipment covers chemiluminescence immunoassay analyzer, enzyme labeling instrument, plate washer, laboratory analyzer, automatic sample processing system, automatic chemiluminescence analyzer and other products.
2022 Informatization of China's Rehabilitation Industry
The rehabilitation industry caught the attention of the Chinese government again in 2021, and the industry entered a phase of accelerated development. The rehabilitation industry will first supplement medical resources and continue to explore a rehabilitation model that suits China's actual conditions. Under this context, EqualOcean Intelligence, together with Neusoft Group, released the 2022 Research Report On the Informatization of China's Rehabilitation Industry.
Sep 01, 2022 10:11 AM
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Insight Lifetech Completes Series D+ Equity Round
Insight Lifetech, a high-tech company dedicated to providing innovative solutions for cardiovascular disease precision intervention, will continue to provide more innovative products and services and provide changes to precision diagnosis and treatment of cardiovascular diseases.
Sep 30, 2022 12:20 PM
MIGS Developer Health Guard Biomed Nets CNY 100 Mn in Series A Round
This financing round is mainly used to promote the multicenter clinical trials of the company's micro-invasive glaucoma products and accelerate the R&D, clinical application and production of other innovative ophthalmic products.
Sep 19, 2022 06:06 PM